Compare Amylx Pharmaceuticals Inc (AMLX) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Noble Corporation plc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.31 (market cap $1.98B), while Noble Corporation plc trades at $41.36 (market cap $6.38B). The key difference: Noble Corporation plc is far larger — about 3.2× Amylx Pharmaceuticals Inc's market cap, and Noble Corporation plc pays a 5% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | NE | |
|---|---|---|
Market Cap | $1.98B | $6.38B |
Sector | Health | Technology |
52-Week High | $18.70 | $54.37 |
52-Week Low | $7.64 | $25.70 |
Enterprise Value | $1.70B | $7.63B |
Dividend Yield | — | 5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Noble Corporation (NE) trades at $39.97, up 2.75% today, with a bearish technical signal and mixed quarterly earnings. The company maintains solid cash flow, with $228M net cash flow in 2025, and recently secured a three-well UKCS contract from BP. Valuation metrics show a P/E of 27.95 and EV/EBITDA of 7.2, while analyst consensus is divided with a $50 price target.
Outlook is cautious due to recent earnings misses and bearish technicals, but strong operational cash flow and new contracts offer stability. Risks include execution challenges and oil market volatility, while the dividend and low leverage provide shareholder support. Investors should weigh fundamental strength against near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
